| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2014: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
|
|---|
| Outline of Final Research Achievements |
The purposes of this study were the elucidation of the mechanism for the pathogenesis of lymphangioma, the exploration of seeds for new therapeutic methods for the disease.
In this study, we established technique to make primary culture cells derived from lymphangioma lesions. And, we analyzed abnormally expressed genes, which we obtained from previous analysis of the cell, as a lymphangioma-related gene.
Recently, two Kampo medicines were reported to be effective for Lymphangimoma. We examined these drugs' direct effect on Lymphangioma derived cell. We co-cultured Lymphangioma cells with Kampo medicines and their crude drugs. They reduced proliferation rate, cell migration, and tube formation. Then, permeability of the cell sheet was increased. Our basic study supported that Kampo medicine could be a therapeutic option for lymphangioma.
|
